Caricamento...
Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction
BACKGROUND: Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits in using Group 1 PH therapies in these patients, particularly in seve...
Salvato in:
| Pubblicato in: | J Thorac Dis |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
AME Publishing Company
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8024797/ https://ncbi.nlm.nih.gov/pubmed/33841939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd-20-1635 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|